ABVC BIOPHARMA, INC.ABVCEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ABVC Q3 2025 Key Financial Metrics
Revenue
$796.0K
Gross Profit
$796.0K
Operating Profit
$-1.2M
Net Profit
$-1.2M
Gross Margin
100.0%
Operating Margin
-146.8%
Net Margin
-156.6%
YoY Growth
104.5%
EPS
$-0.05
Financial Flow
ABVC BIOPHARMA, INC. Q3 2025 Financial Summary
ABVC BIOPHARMA, INC. reported revenue of $796.0K for Q3 2025, with a net profit of $-1.2M (-156.6% margin). Cost of goods sold was $0, operating expenses totaled $2.0M.
Key Financial Metrics
| Total Revenue | $796.0K |
|---|---|
| Net Profit | $-1.2M |
| Gross Margin | 100.0% |
| Operating Margin | -146.8% |
| Report Period | Q3 2025 |
ABVC BIOPHARMA, INC. Annual Revenue by Year
ABVC BIOPHARMA, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $509.6K).
| Year | Annual Revenue |
|---|---|
| 2024 | $509.6K |
| 2023 | $152.4K |
| 2022 | $969.8K |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6109 | $15884 | $2165 | $1205 | $117142 | $389276 | $1966 | $795950 |
| YoY Growth | -98.0% | -62.4% | -99.6% | -99.1% | 1817.5% | 2350.7% | -9.2% | 104.5% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.3M | $16.6M | $14.5M | $14.5M | $14.6M | $14.5M | $7.5M | $21.2M |
| Liabilities | $9.7M | $7.5M | $6.4M | $7.0M | $6.8M | $6.5M | $6.8M | $6.7M |
| Equity | $-379315 | $9.1M | $8.4M | $7.8M | $8.3M | $8.4M | $1.2M | $12.1M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-899827 | $-1.4M | $-479460 | $-473161 | $-1.0M | $171724 | $-493611 | $-133257 |